We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

65 hedge funds and large institutions have $312M invested in Astria Therapeutics in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

168% more call options, than puts

Call options by funds: $316K | Put options by funds: $118K

155% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 11

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

7% more funds holding

Funds holding: 61 → 65 (+4)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

4% less capital invested

Capital invested by funds: $326M → $312M (-$14.2M)

46.87% less ownership

Funds ownership: 130.51% → 83.64% (-47%)

Holders
65
Holders Change
+4
Holders Change %
+6.56%
% of All Funds
1.04%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
28
Reduced
11
Closed
11
Calls
$316K
Puts
$118K
Net Calls
+$198K
Net Calls Change
-$2.79M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$8.96M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$6.57M
3
BlackRock
BlackRock
New York
+$2.66M
4
IC
Ikarian Capital
Texas
+$2.63M
5
LGM
Logos Global Management
California
+$2.43M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$8.79M
2
TLP
Tri Locum Partners
New York
-$5.09M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.35M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.82M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
26
Boothbay Fund Management
New York
$1.87M +$457K +33,801 +32%
Jane Street
27
Jane Street
New York
$1.35M +$1.23M +90,840 +826%
SVCM
28
Saturn V Capital Management
Texas
$1.35M -$921K -68,154 -40%
SCM
29
Silverarc Capital Management
Massachusetts
$1.25M +$171K +12,619 +16%
Morgan Stanley
30
Morgan Stanley
New York
$1.12M +$866K +64,024 +323%
State Street
31
State Street
Massachusetts
$976K +$339K +25,100 +52%
Goldman Sachs
32
Goldman Sachs
New York
$960K +$976K +72,157 New
EI
33
EAM Investors
California
$959K -$260K -19,216 -21%
DCM
34
DAFNA Capital Management
California
$929K +$945K +69,883 New
Ensign Peak Advisors
35
Ensign Peak Advisors
Utah
$865K – – –
SSA
36
Schonfeld Strategic Advisors
New York
$703K +$213K +15,737 +42%
Renaissance Technologies
37
Renaissance Technologies
New York
$642K -$459K -33,961 -41%
Northern Trust
38
Northern Trust
Illinois
$632K +$285K +21,084 +80%
CCIA
39
Campbell & Co Investment Adviser
Maryland
$535K +$544K +40,202 New
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$499K +$269K +19,875 +113%
BCM
41
Bridgeway Capital Management
Texas
$466K – – –
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$453K +$291K +21,517 +171%
Barclays
43
Barclays
United Kingdom
$439K +$446K +32,997 New
Marshall Wace
44
Marshall Wace
United Kingdom
$412K +$217K +16,045 +107%
MFS
45
Mirabella Financial Services
United Kingdom
$380K +$386K +28,585 New
SB
46
Samsara BioCapital
California
$333K – – –
Citadel Advisors
47
Citadel Advisors
Florida
$250K -$1.63M -120,562 -87%
CSS
48
Cubist Systematic Strategies
Connecticut
$231K -$82.5K -6,099 -26%
Verition Fund Management
49
Verition Fund Management
Connecticut
$223K +$227K +16,794 New
OC
50
Oppenheimer & Co
New York
$213K +$149 +11 +0.1%
1
2
3 4

ATXS Hedge Fund Activity: Q1 2023 in Review

65 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2023, worth a combined $312M — down 4.4% from $326M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ATXS positions and 11 closed out — a net gain of 4 holders — while 28 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $8.96M. The largest seller was Cormorant Asset Management, cutting an estimated $8.79M.

  • 65 institutional investors held Astria Therapeutics (ATXS) as of Q1 2023, up from 61 in Q4 2022.
  • Funds reported $312M of Astria Therapeutics stock for Q1 2023, down 4.4% quarter-over-quarter.
  • 15 funds opened new Astria Therapeutics positions in Q1 2023 and 11 closed out, a net change of +4 holders.
  • The largest Astria Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $8.96M added.
  • The largest Astria Therapeutics seller in Q1 2023 was Cormorant Asset Management, an estimated $8.79M sold.

Based on aggregated 13F filings for Q1 2023.